ClinicalTrials.gg
CompletedNCT02608476Updated Nov 20, 2020Results posted

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)

A Phase 3 interventional study of CB-03-01 cream, 1% and Vehicle cream in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 52 sites in 6 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Cassiopea SpA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
732
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
Largest of 19
732 · median 50
Started
2015
the only one that year
Phase 3
5 of 19
2 open now
Registered
3rd of 19
by date
Lead sponsor
4 of 19
Cassiopea SpA

Among the 19 studies testing clascoterone in Acne Vulgaris, this one has the largest enrollment, is the only one that started in 2015, is one of 5 in phase 3, and was the 3rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
  • clascoterone
  • anti-androgen
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is male or non-pregnant female, 9 years of age or older. Females must be , surgically sterile, or using highly effective methods. Women of must have a negative urine pregnancy test (UPT) at the Screening/Baseline Visit.
  2. Subject has provided written and verbal /assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing.
  3. Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4 (severe) [0 (clear) to 4 (severe) scale].
  4. Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones).
  5. Subject and parent/guardian (if applicable) are willing to comply with study instructions and return to the clinic for required visits.
  6. Subject has used the same type and brand of make-up, other facial products (exclusive of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
  3. Subject has greater than two (2) facial nodules.
  4. Subject has nodulocystic acne.
  5. Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  6. Subject is currently enrolled in an drug or device study.
  7. Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (Baseline).
  8. Subject has facial hair that could interfere with the study assessments in the opinion of the investigator.
  9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
  10. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.
  11. Subject has known or previous allergic reaction to any of the active or inactive components of the test articles.
  12. Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.
  13. Subject has used any of the prohibited topical anti-acne treatments or procedures prior to the study unless appropriate is documented.
  14. Subject has used used any of the prohibited systemic anti-acne medications prior to the study unless appropriate washout period is documented.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
732 participants (actual)

Study arms

  • Experimental
    CB-03-01 cream

    CB-03-01 cream, 1% applied twice daily for 12 weeks

    Drug: CB-03-01 cream, 1%

  • Placebo comparator
    Vehicle cream

    Vehicle cream applied twice daily for 12 weeks

    Drug: Vehicle cream

Interventions

  • CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

    Also known as: cortexolone 17α-propionate, clascoterone (USAN, INN)

  • DrugVehicle cream

    Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

    Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

    Time frame: Week 12

  2. Change From Baseline in Non-inflammatory Lesion (NIL) Counts

    Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Inflammatory Lesion (IL) Counts

    Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Total Lesion Counts

    Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in Total Lesion Counts

    Percent change from Baseline in total lesions counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Non-inflammatory Lesion Counts

    Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in Inflammatory Lesion Counts

    Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

    Time frame: Baseline and Week 12

Other outcomes

  1. Local Site Reactions

    Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).

    Time frame: Baseline, Weeks 4, 8, and 12

07

Results

Posted Nov 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneCB-03-01 CreamVehicle Cream
Started369363
Completed302282
Not completed6781
Withdrew: Withdrawal by subject3037
Withdrew: Lost to follow-up2424
Withdrew: Adverse event28
Withdrew: Withdrawal by parent/guardian54
Withdrew: Noncompliance with treatment15
Withdrew: Lack of efficacy31
Withdrew: Other01
Withdrew: Physician decision10
Withdrew: Pregnancy01
Withdrew: Progressive disease10

Outcome measures

PrimaryPercentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

Time frame:
Week 12
Reported as:
Number · Percentage of subjects
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)
Percentage of subjectsCB-03-01 CreamVehicle Cream
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)20.36.5
PrimaryChange From Baseline in Non-inflammatory Lesion (NIL) Counts

Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · Non-inflammatory lesions
Change From Baseline in Non-inflammatory Lesion (NIL) Counts
Non-inflammatory lesionsCB-03-01 CreamVehicle Cream
Change From Baseline in Non-inflammatory Lesion (NIL) Counts-19.4 (-22.1 to -16.7)-10.8 (-13.6 to -8.0)
PrimaryChange From Baseline in Inflammatory Lesion (IL) Counts

Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · Inflammatory lesions
Change From Baseline in Inflammatory Lesion (IL) Counts
Inflammatory lesionsCB-03-01 CreamVehicle Cream
Change From Baseline in Inflammatory Lesion (IL) Counts-20.0 (-21.7 to -18.3)-12.6 (-14.3 to -10.8)
SecondaryChange From Baseline in Total Lesion Counts

Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · total lesions
Change From Baseline in Total Lesion Counts
total lesionsCB-03-01 CreamVehicle Cream
Change From Baseline in Total Lesion Counts-40.0 (-43.8 to -36.2)-23.6 (-27.8 to -19.5)
SecondaryPercent Change From Baseline in Total Lesion Counts

Percent change from Baseline in total lesions counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Total Lesion Counts
percent changeCB-03-01 CreamVehicle Cream
Percent Change From Baseline in Total Lesion Counts-37.3 (-41.1 to -33.6)-22.1 (-26.1 to -18.1)
SecondaryPercent Change From Baseline in Non-inflammatory Lesion Counts

Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Non-inflammatory Lesion Counts
percent changeCB-03-01 CreamVehicle Cream
Percent Change From Baseline in Non-inflammatory Lesion Counts-29.3 (-33.7 to -24.9)-15.6 (-20.3 to -10.9)
SecondaryPercent Change From Baseline in Inflammatory Lesion Counts

Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Inflammatory Lesion Counts
percent changeCB-03-01 CreamVehicle Cream
Percent Change From Baseline in Inflammatory Lesion Counts-46.9 (-50.9 to -42.8)-29.6 (-33.9 to -25.3)
Other pre-specifiedLocal Site Reactions

Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).

Time frame:
Baseline, Weeks 4, 8, and 12

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.. Non-serious events are listed at a 0.8% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CB-03-01 Cream0/369 (0%)0/369 (0%)21/369 (5.7%)
Vehicle Cream0/363 (0%)1/363 (0.3%)34/363 (9.4%)
Most frequent serious events
Most frequent serious events
EventCB-03-01 CreamVehicle Cream
HaematomaVascular disorders0/3691/363
Most frequent other events
Most frequent other events
EventCB-03-01 CreamVehicle Cream
NasopharyngitisInfections and infestations3/3697/363
RhinorrhoeaRespiratory, thoracic and mediastinal disorders3/3695/363
Upper respiratory tract infectionInfections and infestations1/3694/363
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/3694/363
HeadacheNervous system disorders4/3693/363
PyrexiaGeneral disorders0/3693/363
CoughRespiratory, thoracic and mediastinal disorders0/3693/363
AcneSkin and subcutaneous tissue disorders1/3693/363
DiarrhoeaGastrointestinal disorders2/3693/363
BronchitisInfections and infestations3/3690/363

Baseline characteristics

Intent-to-Treat population; defined as all subjects randomized and whom received at least one dose of study medication, including vehicle.

Age, Continuous
Age, Continuous(years)CB-03-01 CreamVehicle CreamTotal
Mean19.3 ± 5.619.0 ± 5.419.2 ± 5.5
Sex: Female, Male
Sex: Female, Male(Participants)CB-03-01 CreamVehicle CreamTotal
Female243221464
Male126142268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CB-03-01 CreamVehicle CreamTotal
Hispanic or Latino20929
Not Hispanic or Latino349354703
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CB-03-01 CreamVehicle CreamTotal
American Indian or Alaska Native112
Asian044
Native Hawaiian or Other Pacific Islander011
Black or African American7613
White357348705
More than one race011
Unknown or Not Reported426
Baseline IGA
Baseline IGA(Participants)CB-03-01 CreamVehicle CreamTotal
0 - Clear000
1 - Almost Clear000
2 - Mild000
3 - Moderate305313618
4 - Severe6450114
Baseline Acne Lesion Counts
Baseline Acne Lesion Counts(lesions)CB-03-01 CreamVehicle CreamTotal
Non-inflammatory lesions62.8 ± 21.463.3 ± 20.563.1 ± 21.0
Inflammatory lesions42.9 ± 12.241.3 ± 11.042.1 ± 11.6
Total Lesions105.7 ± 25.8104.6 ± 24.2105.2 ± 25.0
08

Study locations

52 sites
  • Clear dermatology & Aesthetic Center
    Scottsdale, Arizona 85255, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Belleair Research Center
    Pinellas Park, Florida 33781, United States
  • Arlington Dermatology
    Arlington Heights, Illinois 60005, United States
  • Kansas City Dermatology, PA
    Overland Park, Kansas 66215, United States
  • Maryland Laser Skin and Vein Institute
    Hunt Valley, Maryland 21030, United States
  • Sadick Research Group, LLC
    New York, New York 10075, United States
  • Skin Specialty Dermatology
    New York, New York 10155, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Progressive Clinical Research, PA
    San Antonio, Texas 78229, United States
  • Site 3521
    Plovdiv, 4000, Bulgaria
  • Site 3523
    Sofia, 1000, Bulgaria
  • Site 3525
    Sofia, 1404, Bulgaria
  • 3520
    Sofia, 1407, Bulgaria
  • Site 3524
    Sofia, 1407, Bulgaria
  • Site 3519
    Sofia, 1431, Bulgaria
  • Site 3526
    Sofia, 1618, Bulgaria
  • Site 3522
    Varna, 9010, Bulgaria
  • Site 9923
    Batumi, 6010, Georgia
  • Site 9924
    Kutaisi, 4600, Georgia
  • Site 9921
    Tbilisi, 0145, Georgia
  • Site 9920
    Tbilisi, 0177, Georgia
  • Site 9922
    Tbilisi, 0186, Georgia
  • Site 9925
    Zugdidi, 2100, Georgia
  • 4819
    Bydgoszcz, 85-863, Poland
  • Site 4814
    Czestochowa, 15-794, Poland
  • Site 4822
    Czestochowa, 42-217, Poland
  • 4815
    Katowice, 40-611, Poland
  • Site 4811
    Katowice, 62-069, Poland
  • Site 4821
    Kraków, 30-002, Poland
  • Site 4815
    Kraków, 40-611, Poland
  • Site 4813
    Kraków, 70-332, Poland
  • Site 4823
    Osielsko, 86-031, Poland
  • Site 4816
    Rzeszów, 61-113, Poland
  • Site 4812
    Szczecin, 51-685, Poland
  • Site 4818
    Warszawa, 02-106, Poland
  • Site 4820
    Łódź, 91-334, Poland
  • Site 4033
    Sector 2, Bucharest 020125, Romania
  • Site 4034
    Sector 2, Bucharest 020125, Romania
  • Site 4031
    Sector 3, Bucharest 030303, Romania
  • Site 4029
    Sector 6, Bucharest 062272, Romania
  • Site 4028
    Târgovişte, Jud. Dambovita, Romania
  • Site 4036
    Bucarest, 010825, Romania
  • Site 4035
    Bucharest, 011025, Romania
  • Site 4032
    Craiova, 200642, Romania
  • Site 4037
    Iaşi, 700381, Romania
  • Site 4030
    Sibiu, 550245, Romania
  • Site 8138
    Belgrade, 11050, Serbia
  • Site 8137
    Belgrade, 8137, Serbia
  • Site 8136
    Novi Sad, 21000, Serbia
09

References and documents

Publications

  • Piszczatoski CR, Powell J. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years. Clin Ther. 2021 Oct;43(10):1638-1644. doi: 10.1016/j.clinthera.2021.08.007. Epub 2021 Oct 2. PubMed 34607697 ↗
  • Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. PubMed 32320027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Feb 2018, 27 months.

Results were first posted in Nov 2020, 2 years 8 months after primary completion. A results delay was requested in Jun 2019.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 27 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2015
First posted
Nov 18, 2015
StartActual
Nov 16, 2015
Primary completionActual
Feb 21, 2018
CompletionActual
Feb 21, 2018
Results delay requested
Jun 10, 2019
Results first posted
Nov 20, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02608476
Lead sponsor
Cassiopea SpA
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Nov 16, 2015
Primary completion
Feb 21, 2018
Completion
Feb 21, 2018
Results posted
Nov 20, 2020
Last update
Nov 20, 2020

Study contacts

R&D Cassiopea
study director · Cassiopea S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion